Would you use sequential CDK 4/6 inhibitors in HR-positive metastatic breast CA in successive lines of therapy and change the endocrine agent?
For example first-line ribociclib/letrozole, and second-line palbociclib/fulvestrant? Without data, would there be any expected benefit?
Answer from: Medical Oncologist at Community Practice
There is no preclinical or clinical data to support this approach at this time. I would not use sequential therapy in the absence of data. Several studies are ongoing to evaluate whether continued suppression of this pathway in the face of disease progression benefits patients. Until those studies h...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
It is unclear what to do after progression on CDK4/6- endocrine therapy combination therapy. One option—without much data so far—might be to change the backbone of endocrine therapy only, for example, from an AI to fulvestrant while continuing CDK4/6 inhibition beyond progressi...